Budget 2026-27: A Ray of Hope for Cancer Patients
The Union Budget 2026-27 has brought a much-needed ray of hope for cancer patients and their families across India. One of the most impactful announcements is the exemption of basic customs duty on 17 critical cancer drugs and medicines, many of which are essential for advanced and targeted therapies.
Cancer treatment is often a long, complex, and financially draining journey, especially when it involves imported medicines. The high cost of drugs can be a significant barrier to timely and effective treatment for many patients. By removing customs duty on these medicines, the government aims to make cancer care more accessible and affordable.
The list of exempted drugs covers a wide range of treatments for various types of cancer, including breast cancer, lung cancer, blood cancer, prostate cancer, and aggressive or rare forms. These drugs are part of modern oncology care, encompassing immunotherapy, targeted therapy, and cell-based treatments.
But what does this exemption mean for patients? Customs duty is a tax on imported goods, and its removal directly reduces the cost of these medicines. Patients will now have access to these life-saving drugs at a lower price, as importers and hospitals won't have to pay the basic customs duty.
This move is a significant step towards making cancer care more affordable and accessible. For patients who often require prolonged treatment, even a small reduction in drug prices can make a substantial difference over time. The 17 cancer drugs exempted in Budget 2026-27 are:
- Ribociclib
- Abemaciclib
- Talycabtagene autoleucel
- Tremelimumab
- Venetoclax
- Ceritinib
- Brigatinib
- Darolutamide
- Toripalimab
- Serplulimab
- Tislelizumab
- Inotuzumab ozogamicin
- Ponatinib
- Ibrutinib
- Dabrafenib
- Trametinib
- Ipilimumab
These drugs are widely used in advanced cancer care, including targeted therapy and immunotherapy. The exemption of basic customs duty on these medicines is a clear signal of the government's commitment to making healthcare more affordable.
While the overall cost of cancer treatment remains high, this step is a positive move towards reducing out-of-pocket expenses for patients. Experts believe that these measures, combined with improved health insurance coverage and domestic drug manufacturing, can gradually enhance cancer care accessibility in India. As the Budget 2026-27 unfolds, this announcement is a significant step towards supporting thousands of families facing the emotional and financial challenges of cancer treatment.
Published By: Smarica Pant
Published On: February 1, 2026
